163 related articles for article (PubMed ID: 24016739)
1. Human papillomavirus vaccines in Picardy, France: coverage and correlation with socioeconomic factors.
Ganry O; Bernin-Mereau AS; Gignon M; Merlin-Brochard J; Schmit JL
Rev Epidemiol Sante Publique; 2013 Oct; 61(5):447-54. PubMed ID: 24016739
[TBL] [Abstract][Full Text] [Related]
2. HPV vaccination in France: uptake, costs and issues for the National Health Insurance.
Fagot JP; Boutrelle A; Ricordeau P; Weill A; Allemand H
Vaccine; 2011 Apr; 29(19):3610-6. PubMed ID: 21382486
[TBL] [Abstract][Full Text] [Related]
3. Socioeconomic inequalities to accessing vaccination against human papillomavirus in France: Results of the Health, Health Care and Insurance Survey, 2012.
Guthmann JP; Pelat C; Célant N; Parent du Chatelet I; Duport N; Rochereau T; Lévy-Bruhl D
Rev Epidemiol Sante Publique; 2017 Apr; 65(2):109-117. PubMed ID: 28238476
[TBL] [Abstract][Full Text] [Related]
4. [HPV prophylactic vaccine coverage and factors impacting its practice among students and high school students in Marseilles' area].
Baudoin A; Sabiani L; Oundjian F; Tabouret E; Agostini A; Courbière B; Boubli L; Carcopino X
J Gynecol Obstet Biol Reprod (Paris); 2015 Feb; 44(2):126-35. PubMed ID: 24703591
[TBL] [Abstract][Full Text] [Related]
5. Age impact on human papillomavirus vaccination in France in 2014: A study from the National Health Insurance Database.
Héquet D; Pouget N; Estevez JP; Robain M; Rouzier R
Bull Cancer; 2015 Nov; 102(11):892-7. PubMed ID: 26526386
[TBL] [Abstract][Full Text] [Related]
6. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus vaccine in adolescent women: a 2012 update.
Etter DJ; Zimet GD; Rickert VI
Curr Opin Obstet Gynecol; 2012 Oct; 24(5):305-10. PubMed ID: 22781077
[TBL] [Abstract][Full Text] [Related]
8. Human Papillomavirus vaccination in general practice in France, three years after the implementation of a targeted vaccine recommendation based on age and sexual history.
Thierry P; Lasserre A; Rossignol L; Kernéis S; Blaizeau F; Stheneur C; Blanchon T; Levy-Bruhl D; Hanslik T
Hum Vaccin Immunother; 2016; 12(2):528-33. PubMed ID: 26309144
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus vaccination coverage among Greek higher education female students and predictors of vaccine uptake.
Donadiki EM; Jiménez-García R; Hernández-Barrera V; Carrasco-Garrido P; López de Andrés A; Velonakis EG
Vaccine; 2012 Nov; 30(49):6967-70. PubMed ID: 23022147
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with initiation and completion of human papillomavirus vaccine series among young women enrolled in Medicaid.
Cook RL; Zhang J; Mullins J; Kauf T; Brumback B; Steingraber H; Mallison C
J Adolesc Health; 2010 Dec; 47(6):596-9. PubMed ID: 21094437
[TBL] [Abstract][Full Text] [Related]
11. HPV vaccination coverage in French girls attending middle and high schools: a declarative cross sectional study in the department of Côte d'Or.
Bertaut A; Chavanet P; Aho S; Astruc K; Douvier S; Fournel I
Eur J Obstet Gynecol Reprod Biol; 2013 Oct; 170(2):526-32. PubMed ID: 23953913
[TBL] [Abstract][Full Text] [Related]
12. Papillomavirus vaccine coverage and its determinants in South-Eastern France.
Lions C; Pulcini C; Verger P
Med Mal Infect; 2013 May; 43(5):195-201. PubMed ID: 23582828
[TBL] [Abstract][Full Text] [Related]
13. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
Bogaards JA; Coupé VM; Xiridou M; Meijer CJ; Wallinga J; Berkhof J
Epidemiology; 2011 Jul; 22(4):505-15. PubMed ID: 21540743
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention.
Garland SM; Brotherton JM; Skinner SR; Pitts M; Saville M; Mola G; Jones RW
Vaccine; 2008 Aug; 26 Suppl 12():M80-8. PubMed ID: 18945417
[TBL] [Abstract][Full Text] [Related]
15. Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women.
Kahn JA; Rosenthal SL; Jin Y; Huang B; Namakydoust A; Zimet GD
Obstet Gynecol; 2008 May; 111(5):1103-10. PubMed ID: 18448742
[TBL] [Abstract][Full Text] [Related]
16. Utilization of administrative data to assess the association of an adolescent health check-up with human papillomavirus vaccine uptake in Germany.
Rieck T; Feig M; Deleré Y; Wichmann O
Vaccine; 2014 Sep; 32(43):5564-9. PubMed ID: 25131739
[TBL] [Abstract][Full Text] [Related]
17. Catching up with the catch-up: HPV vaccination coverage data for Australian women aged 18-26 years from the National HPV Vaccination Program Register.
Brotherton J; Gertig D; Chappell G; Rowlands L; Saville M
Commun Dis Intell Q Rep; 2011 Jun; 35(2):197-201. PubMed ID: 22010515
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France.
Miranda S; Chaignot C; Collin C; Dray-Spira R; Weill A; Zureik M
Vaccine; 2017 Aug; 35(36):4761-4768. PubMed ID: 28750853
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil.
Haupt RM; Sings HL
J Adolesc Health; 2011 Nov; 49(5):467-75. PubMed ID: 22018560
[TBL] [Abstract][Full Text] [Related]
20. Will vaccinated women attend cervical screening? A population based survey of human papillomavirus vaccination and cervical screening among young women in Victoria, Australia.
Brotherton JM; Mullins RM
Cancer Epidemiol; 2012 Jun; 36(3):298-302. PubMed ID: 22204834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
